Quick Answer
TherapeuticsMD, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $69.96 million for the year ending 2022.
- TherapeuticsMD, Inc. showed an increase of +2,619.1% in Revenue From Contract With Customer Excluding Assessed Tax from 2021 to 2022.
- This data is from TherapeuticsMD, Inc.'s annual report (Form 10-K), filed with the SEC on April 7, 2023.
- XBRL data for this metric is available from 2016 to 2022 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $3.99 million | Q2 2017: $4.25 million | Q3 2017: $4.42 million | Q4 2017: $4.13 million | Q1 2018: $3.77 million | Q2 2018: $3.76 million | Q3 2018: $3.47 million | Q4 2018: $5.09 million | Q1 2019: $3.95 million | Q2 2019: $6.08 million | Q3 2019: $23.72 million | Q4 2019: $15.90 million | Q1 2020: $12.25 million | Q2 2020: $10.70 million | Q3 2020: $19.34 million | Q4 2020: $22.58 million | Q1 2021: $19.87 million | Q2 2021: $23.00 million | Q3 2021: $25.41 million | Q4 2021: $18.68 million | Q1 2022: $695.0 thousand | Q2 2022: $348.0 thousand | Q3 2022: $354.0 thousand | Q1 2023: $416.0 thousand | Q2 2023: $437.0 thousand | Q3 2023: -$53.0 thousand.
- Over the full 7 years of available data (2016 to 2022), TherapeuticsMD, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 261.4%.
- Historical annual values: Fiscal year 2022: $69.96 million | Fiscal year 2021: $2.57 million | Fiscal year 2020: $64.87 million | Fiscal year 2019: $49.65 million | Fiscal year 2018: $16.10 million | Fiscal year 2017: $16.78 million | Fiscal year 2016: $19.36 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: